The global liquid biopsy market size was estimated at USD 11.85 billion in 2024 and is projected to reach USD 22.88 billion by 2030, growing at a CAGR of 11.5% from 2025 to 2030. Market growth is being driven by several key factors, including the increasing global prevalence of cancer, continuous advancements in cancer diagnostic technologies, and the rising preference for minimally invasive diagnostic procedures that offer faster, safer, and more convenient testing compared to traditional tissue biopsies.

In addition, ongoing research aimed at improving liquid biopsy assays and diagnostic tests—supported by the rapid development and adoption of multi-cancer early detection (MCED) tests—is creating significant opportunities for overall market expansion. These advancements enable earlier detection, improve patient outcomes, and support personalized cancer management.

Liquid biopsy represents a highly advanced diagnostic approach designed to detect tumor-related genetic alterations through a simple blood draw or other bodily fluids. Beyond identifying mutations, the technology is also used to stratify tumors and guide the selection of personalized cancer therapies. For example, in January 2023, Guardant Health received FDA approval for its Guardant360 CDx liquid biopsy assay as a companion diagnostic for identifying ESR1 mutant breast cancer. Such innovations, regulatory approvals, and industry-wide efforts to expand the applications of liquid biopsy are contributing to widespread clinical adoption, thereby driving the market forward.

Key Market Trends & Insights:

• In 2024, North America dominated the global liquid biopsy market, accounting for the largest revenue share of 51.15%. The region’s leadership is driven by strong healthcare infrastructure, high adoption of advanced diagnostic technologies, well-established research facilities, and significant investment in oncology and precision medicine.

• Within North America, the U.S. accounted for the largest market revenue share in 2024, reflecting the country’s extensive healthcare network, high patient awareness, and the presence of major market players actively investing in liquid biopsy innovations and approvals.

• By technology, the multi-gene-parallel analysis (NGS) segment led the market with a revenue share of 76.17% in 2024. This segment’s dominance can be attributed to the increasing demand for high-throughput, comprehensive genomic profiling that enables precise mutation detection, early cancer diagnosis, and personalized treatment strategies.

• In terms of biomarkers, the circulating tumor cells (CTC) segment held the largest revenue share of 35.67% in 2024. CTC-based liquid biopsies are widely used due to their ability to provide critical information about tumor progression, metastatic potential, and response to therapy, making them a preferred choice in clinical oncology.

• By application, the cancer segment dominated with a revenue share of 86.31% in 2024. The high share is driven by the growing global burden of cancer, rising emphasis on early detection, and the integration of liquid biopsy in oncology workflows for diagnosis, prognosis, and therapy monitoring. The adoption of liquid biopsy in cancer management continues to be a key factor driving market growth globally.

Order a free sample PDF of the Liquid Biopsy Market Intelligence Study, published by Grand View Research.

Market Size & Forecast:

• 2024 Market Size: USD 11.85 Billion

• 2030 Projected Market Size: USD 22.88 Billion

• CAGR (2025-2030): 11.5%

• North America: Largest market in 2024

Key Companies & Market Share Insights:

The liquid biopsy industry is propelled by a combination of well-established leaders and dynamic emerging innovators, each leveraging tailored strategies to strengthen their market presence and expand their reach. Leading companies such as ANGLE plc, Oncimmune Holdings PLC, Guardant Health, Myriad Genetics, Inc., Biocept, Inc., Lucence Health Inc., Freenome Holdings, Inc., F. Hoffmann-La Roche Ltd., QIAGEN, Illumina, Inc., Thermo Fisher Scientific, Inc., and Epigenomics AG maintain their market dominance through ongoing innovations in liquid biopsy testing, strategic acquisitions, and collaborations that broaden their service portfolios and reinforce their global footprint.

For example, in November 2023, Illumina Inc. launched the TruSight Oncology 500 ctDNA v2, a next-generation liquid biopsy assay designed for comprehensive genomic profiling. This launch highlights the emphasis of key market players on developing advanced diagnostic solutions that improve early cancer detection, support personalized treatment strategies, and enhance clinical decision-making, all of which continue to drive growth and innovation within the liquid biopsy industry.

Key Players

• ANGLE plc

• Oncimmune Holdings PLC

• Guardant Health

• Myriad Genetics, Inc.

• Biocept, Inc.

• Lucence Health Inc.

• Freenome Holdings, Inc.

• F. Hoffmann-La Roche Ltd.

• QIAGEN

• Illumina, Inc.

• Thermo Fisher Scientific, Inc.

• Epigenomics AG

Explore Horizon Databook – The world's most expansive market intelligence platform developed by Grand View Research.

Conclusion:

The liquid biopsy market is experiencing strong growth, driven by rising cancer prevalence, technological innovations in diagnostics, and a shift toward less-invasive testing. Ongoing development of multi-cancer early detection tests and advanced assays is opening up significant opportunities. Despite some challenges—such as standardization and assay sensitivity—liquid biopsy is increasingly becoming a vital tool in precision oncology, especially for tumor monitoring and personalized therapy.